Biotech Strategy Blog

Commentary on Science, Innovation & New Products

About Pieter Droppert

Here are my most recent posts

Posts by Pieter Droppert

Pfizer next gen ALK inhibitor PF-06463922 could replace Xalkori

Boston – Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics co-hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC).

Leave a comment